A third Covid-19 vaccination dose provides longer and better protection against the Omicron variant of the disease, researchers say.
A study by Mie Agermose Gram at Statens Serum Institut, Copenhagen, Denmark and colleagues suggests that a third Covid-19 vaccine dose increased the level and duration of protection against Omicron infection and hospitalisation, whereas two vaccine doses provide only limited and short-lived protection against SARS-CoV-2 infection with the Omicron variant.
Gram said: “Despite being less effective against infection with Omicron than previous variants, a third mRNA COVID-19 vaccine dose offers better protection against Omicron infection than two doses and protects well against COVID-19 hospitalisation.”
Emergence of new SARS-CoV-2 variants may decrease long-term vaccine durability, increasing the risk of infection and hospitalisation. However, evidence is limited regarding the vaccine effectiveness of three vaccines over time.
In order to estimate the effectiveness of two or three vaccine doses against Covid-19 infection and hospitalisation, researchers conducted a nationwide cohort study of all previously uninfected Danish residents aged 12 and older by accessing individual-level data stored in the national Danish Civil Registration System and Danish Vaccination Registry.
The researchers then estimated vaccine effectiveness using vaccination status as a time-varying exposure, adjusting for age, sex, geographic location, and comorbidities, before comparing infection and hospitalisation rates to unvaccinated individuals.
The researchers found that a third vaccine dose provided greater protection against infection and hospitalisation from the Omicron variant than with two vaccines and also that there was less evidence of waning protection.
Future studies are needed to better understand the durability of a third vaccine dose after 120 days and evaluate the need for subsequent boosters. One limitation of the study was that the data was non-randomised, so there could be unmeasured differences between the vaccinated and unvaccinated groups.
The authors said in their study: “Our findings indicate that a third dose is necessary to maintain protection against infection for a longer time and to ensure a high level of protection against COVID-19 hospitalisation with the Omicron variant.
“Continued emergence of new variants and waning vaccine durability require ongoing evaluation of vaccine effectiveness against infection and hospitalisation to inform future vaccination strategies.”
The study is published in the open-access journal PLOS Medicine.
